First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

Core Insights - IMUNON, Inc. has initiated the Phase 1 clinical trial for its IMNN-101 vaccine, utilizing the proprietary PlaCCine platform aimed at providing a seasonal COVID-19 vaccine [1][2][3] - The trial will evaluate the safety, tolerability, and immune response of IMNN-101 against the SARS-CoV-2 Omicron XBB1.5 variant, with topline data expected by the end of 2024 [2][3] - The company aims to demonstrate that its PlaCCine technology offers superior durability of immune protection compared to existing mRNA vaccines [4][7] Company Overview - IMUNON is a clinical-stage biotechnology company focused on non-viral DNA-mediated immunotherapy, with a portfolio that includes the TheraPlas® and PlaCCine® modalities [4][5] - The lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer currently in Phase 2 development [5] - The company is leveraging its innovative technologies to address challenging medical conditions and enhance patient outcomes [4][5] Clinical Trial Details - The Phase 1 study will enroll 24 participants, testing three escalating doses of IMNN-101, with eight participants per dose [3] - Primary objectives include assessing safety and tolerability, while secondary objectives focus on evaluating neutralizing antibody responses and their durability [3] - Preclinical data suggests that the immune protection from IMNN-101 may exceed that of published mRNA vaccine data, with immunogenicity and stability at workable temperatures enhancing commercial viability [7]